- Medical - Diagnostics & Research
- Healthcare
-
5.70
EPS
-
48.07
P/E
-
198B
MARKET CAP
-
0.38%
DIV YIELD
Company Overview
2200 PENNSYLVANIA AVE. N.W.,WASHINGTON DC 20037-1701,2028280850
CEO
Mr. Rainer M. Blair
Employess
61000
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Website
https://www.danaher.com
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Next Earnings Date
Oct. 22, 2024
Ex Dividends date
Jul. 26, 2024
Dividend Date
June 28, 2024
YTD Performance
16.66%
Fiscal Year End
12-31
IPO Date
1978-12-29
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 2.25% | 3.73% | 2.35% | -24.09% |
| EPS | 5.22% | 11.24% | 9.02% | -34.29% |
| Equity | 9.10% | 13.65% | 10.38% | 6.80% |
| Cash | 6.53% | 49.40% | -0.95% | -2.19% |
| Return On Capital (ROIC) | 7.38% | 7.26% | 8.68% | 5.96% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 1,880 | 591 | 8 | 11 | 212 |
| Long Term Debt | 17,700 | 19,100 | 22,200 | 21,200 | 21,500 |
| LT Finance Leases | 1,130 | 1,060 | 1,100 | 974 | 797 |
| Shares Outstanding | 736 | 725 | 715 | 706 | 715 |
| Market Cap | 170,000 | 171,000 | 208,000 | 139,000 | 97,300 |
Price
News
HTHIY or DHR: Which Is the Better Value Stock Right Now?
2 monthsInvestors looking for stocks in the Diversified Operations sector might want to consider either Hitachi Ltd. (HTHIY) or Danaher (DHR).
zacks.com
Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals
2 monthsThe Investment Committee give you their top stocks to watch for the second half.
youtube.com
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
2 monthsBREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the DxI 9000 Immunoassay Analyzer* was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition.
prnewswire.com
Danaher (DHR) Q2 Earnings Beat, Biotechnology Sales Dip Y/Y
2 monthsDanaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
zacks.com
Danaher Stock Soars on Q2 Earnings Beat
2 monthsDanaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday trading Tuesday.
investopedia.com
Here's Why Danaher Stock Surged Today
2 monthsThe pandemic has created a lot of noise around Danaher's revenue growth, but the dust looks set to settle in 2024. Core revenue and margins were better than expected in the second quarter.
fool.com
Here's What Key Metrics Tell Us About Danaher (DHR) Q2 Earnings
2 monthsThe headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Danaher Corporation (DHR) Q2 2024 Earnings Call Transcript
2 monthsDanaher Corporation (NYSE:DHR ) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P.
seekingalpha.com
Danaher Stock Surges. More Than Earnings Are Driving It Higher.
2 monthsDanaher reports second-quarter adjusted earnings of $1.72 a share on revenue of $5.74 billion.
barrons.com
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
2 monthsDanaher (DHR) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $2.05 per share a year ago.
zacks.com
Danaher beats Q2 profit estimates on strength in medical testing business
2 monthsDanaher beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its genetic testing services, sending shares of the life sciences firm up nearly 8% in premarket trading.
reuters.com
Danaher Reports Second Quarter 2024 Results
2 monthsWASHINGTON , July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted.
prnewswire.com